RARE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ultragenyx Pharmaceutical Inc (RARE) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock lacks immediate positive catalysts, has mixed analyst sentiment, and its financial performance shows declining profitability metrics despite revenue growth. The technical indicators and options data suggest a neutral to slightly bearish sentiment, making it prudent to hold off on investing until clearer signals or catalysts emerge.
The MACD is positive but contracting, indicating weakening bullish momentum. RSI is neutral at 53.509, suggesting no clear overbought or oversold conditions. Moving averages are converging, showing no strong directional trend. The stock is trading near its pivot level of 24.535, with key resistance at 25.75 and support at 23.321.
Analyst Morgan Stanley sees a favorable asymmetric setup with 50%-70% upside potential for GTX-102 Phase 3 data in 2026.
Lack of recent news or significant trading trends from hedge funds, insiders, or Congress.
In Q4 2025, revenue increased to $207.28M, up 25.72% YoY. However, net income dropped to -$128.56M, down -3.62% YoY. EPS also declined to -1.29, down -7.19% YoY. Gross margin decreased to 85.84%, down -4.36% YoY, reflecting challenges in profitability.
Analyst sentiment is mixed. Morgan Stanley raised its price target to $67, citing potential upside from GTX-102 Phase 3 data. However, Goldman Sachs downgraded the stock to Neutral with a price target of $25 due to risks in clinical trial design and disease heterogeneity. Other analysts have lowered price targets but maintain Buy or Outperform ratings, indicating cautious optimism.
